STRUCTURE THERAPEUTICS INC (GPCR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$47.340.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GPCR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -50.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
GPCR — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Structure Therapeutics Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the second quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purpos…
Why it matters: The new CCO's actions will shape the company's market strategy as they prepare to launch products.
Watch forThe new CCO will announce plans or partnerships to improve market access.
Also watch forThe new CCO will not announce major updates or plans in the next few months.
Why it matters: Starting this trial would show progress in developing new treatments for obesity. Positive results could enhance the pipeline.
Supportive ifThe ACCG-2671 MAD trial is initiated as planned in Q3 2026.
Worry ifThe ACCG-2671 MAD trial is delayed or not initiated as expected.
Why it matters: Data from this program will show how well aleniglipron works for weight management. Positive results could support future sales.
Supportive ifData from the ACCOMPLISH program shows good weight loss compared to placebo.
Worry ifData from the ACCOMPLISH program shows no good weight loss compared to placebo.
Why it matters: This data shows how well aleniglipron works for different patient groups.
Watch forPositive results from the Body Composition and Type 2 Diabetes trials show weight loss.
Also watch forNegative data from these trials show no significant weight loss or adverse effects.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$203 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $578 loss on $10,000 · 5.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,174 loss on $10,000 · 61.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on the Phase 3 trials will show progress for regulatory approval. This is important for the company's future.
Watch forManagement says the Phase 3 trials for aleniglipron are on track. They are progressing as planned.
Also watch forManagement announces delays or setbacks in the Phase 3 trials.
Why it matters: Starting these trials is key for aleniglipron's path to market. It shows the drug's development progress.
Supportive ifThe first patients are dosed in the Phase 3 ACCOMPLISH trials.
Worry ifDelays in starting the Phase 3 trials or no patients dosed.
Why it matters: Starting these trials is key for the company's lead product. It shows progress in development.
Supportive ifAnnouncement of the start of Phase 3 trials for the lead product.
Worry ifDelay or cancellation of the Phase 3 trials.
Why it matters: This data will show how well aleniglipron works over 72 weeks. Positive results could support its market potential.
Supportive ifThe ACCESS OLE trial shows good weight loss and tolerability.
Worry ifData shows no major weight loss or high dropout rates.
Why it matters: Early data will show if this new oral amylin therapy is safe and effective.
Supportive ifEarly Phase 1 data for ACCG-2671 shows it is safe and well tolerated.
Worry ifEarly Phase 1 data for ACCG-2671 shows safety issues or that it may not work.
Why it matters: This data will show how aleniglipron affects body fat loss. Good results could help its market position.
Supportive ifThe Body Composition trial shows good body fat loss compared to placebo.
Worry ifData shows no significant body fat loss or negative results.
Why it matters: Starting this trial is key for advancing another treatment option. It shows progress in their pipeline.
Supportive ifThe ACCG-2671 trial for multiple doses has started.
Worry ifDelay in starting the ACCG-2671 multiple ascending dose trial beyond Q3 2026.
Why it matters: The new CCO could improve commercialization efforts for aleniglipron. This could lead to better market access and sales.
Watch forThe new CCO uses methods that help aleniglipron reach the market better.
Also watch forThe new CCO's strategies do not lead to improved market access or sales.
Why it matters: This update will show if the company maintains its cash runway through 2028. A decline could impact future projects.
Worry ifThe cash position is over $1.3 billion. This shows strong funding for operations.
Less concerning ifThe cash position is below $1 billion. This raises concerns about funding future projects.